drugset
drugset / Trial / NCT00605618

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

NCT00605618 ↗

Phase 1/2 Completed 8 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Part A: The purpose of this study is to find the maximum tolerated dose of BMS-777607 in subjects with advanced or metastatic solid tumors Part B: The purpose of this study is to describe the preliminary activity of BMS-77607 in subjects with advanced or metastatic gastroesophageal cancer, hormone refractory prostate cancer, head and neck squamous cell carcinoma, and type I papillary renal cell carcinoma

Timeline

Start
2008-03
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS 777607 Small molecule 10 mg Oral

Indications

cancer